BR112022015897A2 - Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v - Google Patents
Receptores de célula t restritos à classe i de hla contra ras com mutação de g12vInfo
- Publication number
- BR112022015897A2 BR112022015897A2 BR112022015897A BR112022015897A BR112022015897A2 BR 112022015897 A2 BR112022015897 A2 BR 112022015897A2 BR 112022015897 A BR112022015897 A BR 112022015897A BR 112022015897 A BR112022015897 A BR 112022015897A BR 112022015897 A2 BR112022015897 A2 BR 112022015897A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell receptors
- mutation
- restricted
- hla class
- ras
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 102000016914 ras Proteins Human genes 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title abstract 2
- 102200006531 rs121913529 Human genes 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
RECEPTORES DE CÉLULA T RESTRITOS À CLASSE I DE HLA CONTRA RAS COM MUTAÇÃO DE G12V. São descritos receptores de célula T isolados ou purificados (TCRs), em que um TCR tem especificidade antigênica para uma sequência de aminoácido de RAS mutada apresentada pela molécula de classe I de antígeno de leucócito humano (HLA). Polipeptídeos e proteínas relacionados, bem como, ácidos nucleicos relacionados, vetores de expressão recombinantes, células hospedeiras, populações de células e composições farmacêuticas também são fornecidos. São também descritos métodos de detectar a presença de câncer em um mamífero e métodos de tratar ou prevenir câncer em um mamífero.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976655P | 2020-02-14 | 2020-02-14 | |
| US202063060340P | 2020-08-03 | 2020-08-03 | |
| PCT/US2021/017852 WO2021163477A1 (en) | 2020-02-14 | 2021-02-12 | Hla class i-restricted t cell receptors against ras with g12v mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015897A2 true BR112022015897A2 (pt) | 2022-10-18 |
Family
ID=74860482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015897A BR112022015897A2 (pt) | 2020-02-14 | 2021-02-12 | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230082787A1 (pt) |
| EP (1) | EP4103598A1 (pt) |
| JP (1) | JP2023526149A (pt) |
| KR (1) | KR20220143875A (pt) |
| CN (1) | CN115315441A (pt) |
| AU (1) | AU2021220957A1 (pt) |
| BR (1) | BR112022015897A2 (pt) |
| CA (1) | CA3167382A1 (pt) |
| GB (1) | GB2610311A (pt) |
| MX (1) | MX2022009825A (pt) |
| TW (1) | TW202140535A (pt) |
| WO (1) | WO2021163477A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| WO2023232785A1 (en) * | 2022-05-30 | 2023-12-07 | Hs Diagnomics Gmbh | Common tumor-specific t cell receptors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| US20170319638A1 (en) * | 2016-05-06 | 2017-11-09 | Virttu Biologics Limited | Treatment of cancer |
| CA3084246A1 (en) * | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against mutated ras |
| US20210061876A1 (en) * | 2017-12-29 | 2021-03-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | T cell receptors for tumor specific proteasome splice variants and uses thereof |
-
2021
- 2021-02-12 AU AU2021220957A patent/AU2021220957A1/en active Pending
- 2021-02-12 GB GB2211757.6A patent/GB2610311A/en active Pending
- 2021-02-12 KR KR1020227031589A patent/KR20220143875A/ko unknown
- 2021-02-12 CA CA3167382A patent/CA3167382A1/en active Pending
- 2021-02-12 EP EP21710740.8A patent/EP4103598A1/en active Pending
- 2021-02-12 TW TW110105193A patent/TW202140535A/zh unknown
- 2021-02-12 US US17/799,193 patent/US20230082787A1/en active Pending
- 2021-02-12 BR BR112022015897A patent/BR112022015897A2/pt unknown
- 2021-02-12 CN CN202180014281.4A patent/CN115315441A/zh active Pending
- 2021-02-12 WO PCT/US2021/017852 patent/WO2021163477A1/en unknown
- 2021-02-12 JP JP2022549088A patent/JP2023526149A/ja active Pending
- 2021-02-12 MX MX2022009825A patent/MX2022009825A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021220957A1 (en) | 2022-09-01 |
| CA3167382A1 (en) | 2021-08-19 |
| KR20220143875A (ko) | 2022-10-25 |
| GB2610311A (en) | 2023-03-01 |
| WO2021163477A8 (en) | 2022-09-29 |
| MX2022009825A (es) | 2022-10-13 |
| US20230082787A1 (en) | 2023-03-16 |
| JP2023526149A (ja) | 2023-06-21 |
| CN115315441A (zh) | 2022-11-08 |
| WO2021163477A1 (en) | 2021-08-19 |
| EP4103598A1 (en) | 2022-12-21 |
| GB202211757D0 (en) | 2022-09-28 |
| TW202140535A (zh) | 2021-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| Yamada et al. | Preferential expression of cancer/testis genes in cancer stem‐like cells: proposal of a novel sub‐category, cancer/testis/stem gene | |
| BR112022015888A2 (pt) | Receptores de células t restritos a hla classe i contra ras com mutação g12d | |
| BR112021026408A2 (pt) | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 | |
| CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
| MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
| EP2694530B1 (en) | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment | |
| CA3066635A1 (en) | Neoantigen identification, manufacture, and use | |
| EA202090757A1 (ru) | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 | |
| Infantes et al. | Natural HLA-B* 2705 protein ligands with glutamine as anchor motif: implications for HLA-B27 association with spondyloarthropathy | |
| US20220241331A1 (en) | Identification of recurrent mutated neopeptides | |
| Monnot et al. | Staphylococcal phosphatidylglycerol antigens activate human T cells via CD1a | |
| Tailor et al. | Ionizing radiation drives key regulators of antigen presentation and a global expansion of the immunopeptidome | |
| Overgaard et al. | Establishing the pig as a large animal model for vaccine development against human cancer | |
| Duvvuri et al. | The human immune system recognizes neopeptides derived from mitochondrial DNA deletions | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| Schmidt et al. | Serological and immunochemical studies of H‐2 allospecificities on K36, a syngeneic tumour of AKR | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 | |
| Sharma et al. | Differential proteomics approach to identify putative protective antigens of Mycobacterium tuberculosis presented during early stages of macrophage infection and their evaluation as DNA vaccines | |
| US20230197192A1 (en) | Selecting neoantigens for personalized cancer vaccine | |
| WO2022051449A3 (en) | T cell receptors recognizing r273c or y220c mutations in p53 | |
| Vrbanec et al. | Genetic Risk of Tuberculosis is Spread within the Hallmarks of the Disease | |
| JP2024508677A (ja) | 個別化がんワクチン用ネオアンチゲンのランク付け |